BR100 Decreased By (-0.03%)
BR30 Decreased By (-0.19%)
KSE100 Decreased By (-0.25%)
KSE30 Decreased By (-0.48%)
BECO 5.86 Decreased By ▼ -0.17 (-2.82%)
BML 57.79 Increased By ▲ 5.04 (9.55%)
BOP 33.84 Decreased By ▼ -0.41 (-1.2%)
CNERGY 8.16 No Change ▼ 0.00 (0%)
DCL 11.78 Decreased By ▼ -0.56 (-4.54%)
FCCL 53.68 Decreased By ▼ -0.21 (-0.39%)
FCSC 5.47 Increased By ▲ 0.25 (4.79%)
FFL 17.83 Decreased By ▼ -0.20 (-1.11%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.15 Increased By ▲ 0.15 (1.36%)
KEL 8.09 Decreased By ▼ -0.02 (-0.25%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 88.17 Increased By ▲ 0.12 (0.14%)
NBP 183.60 Decreased By ▼ -2.88 (-1.54%)
PACE 11.66 Increased By ▲ 0.94 (8.77%)
PAEL 40.25 Increased By ▲ 0.31 (0.78%)
PIAHCLA 26.16 Decreased By ▼ -0.01 (-0.04%)
PIBTL 17.24 Decreased By ▼ -0.08 (-0.46%)
PPL 230.88 Decreased By ▼ -1.90 (-0.82%)
PRL 34.49 Decreased By ▼ -0.46 (-1.32%)
PTC 67.70 Increased By ▲ 0.14 (0.21%)
SEARL 91.33 Increased By ▲ 0.40 (0.44%)
SSGC 26.89 Decreased By ▼ -0.28 (-1.03%)
TELE 8.57 No Change ▼ 0.00 (0%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.42 Increased By ▲ 0.66 (7.53%)
TREET 24.57 Increased By ▲ 0.03 (0.12%)
TRG 71.99 Increased By ▲ 0.24 (0.33%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
Business & Finance

Germany expects 40.2mn doses of Biontech COVID vaccine in Q2

  • The document, which was prepared for a virtual meeting of Chancellor Angela Merkel with the 16 state premiers and representatives of pharmaceutical companies and the European Union later on Monday.
Published February 1, 2021 Updated February 1, 2021 06:45pm
By

BERLIN: The German government expects 40.2 million doses of Biontech/Pfizer's COVID-19 vaccine in the second quarter, a government document seen by Reuters on Monday showed.

The document, which was prepared for a virtual meeting of Chancellor Angela Merkel with the 16 state premiers and representatives of pharmaceutical companies and the European Union later on Monday, also said that the government sees potential delivery and production risks.

Comments

Comments are closed for this article.